Menu
Search Close

News

Preliminary Results for the Year Ended 30 April 2009

09th September 2009

The Directors of Scancell Holdings plc, the parent company of Scancell Limited (‘Scancell’), the developer of therapeutic cancer and infectious disease vaccines based on its patented ImmunoBody® platform, are pleased to announce the preliminary results for Scancell for the year ended 30th April 2009 (‘the Period’).

Highlights:

  • Admitted to Plus markets and raised £1.559,502
  • Signed deal with Cobra Biomanufacturing Plc to commence Good Manufacturing Practice manufacture of Scancell’s SCIB1 DNA vaccine
  • Awarded £250,000 Grant for Research and Development by the East Midlands Development Agency
  • Preparations for scheduled 2010 Phase 1 clinical trials of Scancell’s first cancer vaccine for melanoma, SCIB1, continued on time and on budget
  • Voted ACQ Magazine Plus Company of the year

Post Period Highlights:

  • Merck Serono: signed licensing agreement for two key patents required for further development and commercialisation of protein ImmunoBody® vaccines
  • Ichor Medical Systems: agreement signed to use Ichor's TriGrid™ electroporation device for the delivery of SCIB1
  • ImmunoVaccine Technologies Inc.: signed a research agreement to explore using IVT’s DepoVax™ delivery system for Scancell’s future ImmunoBody® DNA infectious disease and animal health vaccines
  • Zeus Capital appointed as Corporate Advisor

David Evans, Non-Executive Chairman of Scancell, commented:

“I am pleased to report on Scancell’s first successful year as a public company. The Company continues to make good progress towards commencing Phase 1 clinical trials on its first therapeutic cancer vaccine SCIB1 in 2010..Scancell has also entered into a number of significant agreements that will support both SCIB1 and the development of future ImmunoBody® vaccines.”

For further information contact:

Professor Lindy Durrant  -  Scancell Holdings Plc  -  +44 207 245 1100

Adam Reynolds/Vikki Krause  -  Hansard Group  -  +44 7515 922906

Ross Andrews  -  Zeus Capital  -  +44 (0)161 831 1512

View the full results 

Webcasts, Interviews and Media Coverage

Scancell Holdings lays groundwork for pivotal year

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D

Tue, 20 Aug 2019 06:05:00

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Mon, 19 Aug 2019 06:46:00